Skip Navigation

Annals of Oncology 2004 15(10):1453-1459; doi:10.1093/annonc/mdh383
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (53)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Punt, C. J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Punt, C. J. A.
Related Collections
Right arrow 2004 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society for Medical Oncology

Review

New options and old dilemmas in the treatment of patients with advanced colorectal cancer

C. J. A. Punt*

Department of Medical Oncology, University Medical Center St Radboud, Nijmegen, The Netherlands

* Correspondence to: Prof. C. J. A. Punt, Department of Medical Oncology, University Medical Center, St Radboud, PO Box 9010, 6500 HB Nijmegen, The Netherlands. Tel: +31-24-3610353; Fax: +31-24-3540788; Email: c.punt{at}onco.umcn.nl

With more data on the use of oxaliplatin and irinotecan available, and the recent approval of two signal transduction inhibitors for patients with advanced colorectal cancer, there are now many treatment options to choose from. From the current regimens no straightforward choice can be made that provides any patient with the optimal chance for prolonged survival with the least side-effects. The current data concerning timing and duration of chemotherapy, combination or sequential therapy, preference of agents for first-line treatment, oral fluoropyrimidines, neo-adjuvant chemotherapy for irresectable liver metastases, and the use of signal transduction inhibitors are reviewed.

Key words: bevacizumab, capecitabine, cetuximab, colorectal cancer, irinotecan, oxaliplatin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNMHome page
D. Vriens, H. W.M. van Laarhoven, J. J.A. van Asten, P. F.M. Krabbe, E. P. Visser, A. Heerschap, C. J.A. Punt, L.-F. de Geus-Oei, and W. J.G. Oyen
Chemotherapy Response Monitoring of Colorectal Liver Metastases by Dynamic Gd-DTPA-Enhanced MRI Perfusion Parameters and 18F-FDG PET Metabolic Rate
J. Nucl. Med., November 1, 2009; 50(11): 1777 - 1784.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Tol, M. Koopman, M. C. Miller, A. Tibbe, A. Cats, G. J. M. Creemers, A. H. Vos, I. D. Nagtegaal, L. W. M. M. Terstappen, and C. J. A. Punt
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents
Ann. Onc., October 27, 2009; (2009) mdp463v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Postma, M. Koopman, T. E. Buffart, P. P. Eijk, B. Carvalho, G. J. Peters, B. Ylstra, J. H. van Krieken, C. J. A. Punt, and G. A. Meijer
DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer
Ann. Onc., June 1, 2009; 20(6): 1048 - 1056.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L.-F. de Geus-Oei, D. Vriens, H. W.M. van Laarhoven, W. T.A. van der Graaf, and W. J.G. Oyen
Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 43S - 54S.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Cunningham, B. Sirohi, A. Pluzanska, B. Utracka-Hutka, J. Zaluski, R. Glynne-Jones, P. Koralewski, J. Bridgewater, P. Mainwaring, H. Wasan, et al.
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
Ann. Onc., February 1, 2009; 20(2): 244 - 250.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Koopman, M. T. Seymour, and C. J. A. Punt
The CAIRO and FOCUS Studies: Which Lesson Is to Be Learned?
Oncologist, February 1, 2009; 14(2): 192 - 193.
[Full Text] [PDF]

Home page
 Ann OncolHome page
J. Tol, M. Koopman, C. J. Rodenburg, A. Cats, G. J. Creemers, J. G. Schrama, F. L. G. Erdkamp, A. H. Vos, L. Mol, N. F. Antonini, et al.
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
Ann. Onc., April 1, 2008; 19(4): 734 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Bajetta, L. Celio, E. Ferrario, M. Di Bartolomeo, A. Denaro, K. Dotti, M. Mancin, R. Bajetta, A. Colombo, and S. Pusceddu
Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer
Ann. Onc., November 1, 2007; 18(11): 1810 - 1816.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. de Geus-Oei, B Wiering, P. Krabbe, T. Ruers, C. Punt, and W. Oyen
FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma
Ann. Onc., November 1, 2006; 17(11): 1650 - 1655.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M Koopman, N. Antonini, J Douma, J Wals, A. Honkoop, F. Erdkamp, R. de Jong, C. Rodenburg, G Vreugdenhil, J. Akkermans-Vogelaar, et al.
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study
Ann. Onc., October 1, 2006; 17(10): 1523 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
W. J. Lesterhuis, I. J. M. de Vries, D. H. Schuurhuis, A. C. I. Boullart, J. F. M. Jacobs, A. J. de Boer, N. M. Scharenborg, H. M. H. Brouwer, M. W. M. M. van de Rakt, C. G. Figdor, et al.
Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests
Ann. Onc., June 1, 2006; 17(6): 974 - 980.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Goto, Y. Yamada, H. Yasui, K. Kato, T. Hamaguchi, K. Muro, Y. Shimada, and K. Shirao
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer
Ann. Onc., June 1, 2006; 17(6): 968 - 973.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. A. P. Hospers, M. Schaapveld, J. W. R. Nortier, J. Wils, A. van Bochove, R. S. de Jong, G. J. Creemers, Z. Erjavec, D. J. de Gooyer, P. H. Th. J. Slee, et al.
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer
Ann. Onc., March 1, 2006; 17(3): 443 - 449.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Chong, A. Bhatnagar, D. Cunningham, T. M. Cosgriff, P. G. Harper, W. Steward, J. Bridgewater, M. Moore, J. Cassidy, R. Coleman, et al.
Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer
Ann. Onc., March 1, 2006; 17(3): 437 - 442.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Vincenzi, D. Santini, and G. Tonini
Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan
Ann. Onc., March 1, 2006; 17(3): 527 - 528.
[Full Text] [PDF]

Home page
 Ann OncolHome page
G. Folprecht, A. Grothey, S. Alberts, H.-R. Raab, and C.-H. Kohne
Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates
Ann. Onc., August 1, 2005; 16(8): 1311 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Mattioli, C. Massacesi, F. Recchia, F. Marcucci, C. Cappelletti, L. Imperatori, A. Pilone, M. Rocchi, A. Cesta, G. Laici, et al.
High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer
Ann. Onc., July 1, 2005; 16(7): 1147 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. W. Rea, J. W. R. Nortier, W. W. Ten Bokkel Huinink, S. Falk, D. J. Richel, T. Maughan, G. Groenewegen, J. M. Smit, N. Steven, J. M. Bakker, et al.
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer
Ann. Onc., July 1, 2005; 16(7): 1123 - 1132.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Comella, B. Massidda, G. Filippelli, S. Palmeri, D. Natale, A. Farris, F. De Vita, F. Buzzi, S. Tafuto, L. Maiorino, et al.
Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial
Ann. Onc., June 1, 2005; 16(6): 878 - 886.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H.P. Kalofonos, G. Aravantinos, P. Kosmidis, P. Papakostas, T. Economopoulos, M. Dimopoulos, D. Skarlos, A. Bamias, D. Pectasides, S. Chalkidou, et al.
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study
Ann. Onc., June 1, 2005; 16(6): 869 - 877.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. J. A. Punt
Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
Ann. Onc., June 1, 2005; 16(6): 845 - 846.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.